Clinical Trial Search

Primary: Mortality, Heart Failure-related Urgent Care Visits, or Significant Increase in Left Ventricular End Systolic Volume Index (LVESVI) — 160; 191; 93; 136 participants…

Primary: Number of Patients With Improved Clinical Composite Score — 86; 45 Participants — p=0.001

Primary: Change in Left Ventricle End-Systolic Volume Index (LVESVI) — -11.6; -4.1 mL/m^2 — p=0.0001

Primary: Safety (Subjects Without a Model 4196 Lead Related Complication) — 168 participants

Primary: Minnesota For Living With Heart Failure Questionnaire — 31; 24 units on a scale

Primary: Change in Left Ventricular Ejection Fraction (LVEF) — 26.3; 30.5; 31.9; 34.0 ejection fraction percentage — p=<0.001

Primary: A Positive Success Rate of LBBAP Utilization With Intraprocedural Transthoracic Echocardiogram — 19; 10 Participants

Primary: Safety (Subjects Without a Model 4396 Lead Related Complication) — 155 participants

Primary: Number of Participants Who Remained on Study — 9; 4 participants

Primary: Death, Heart Transplant, Left Ventricular Assist Device Implantation — 35 participants

Primary: • ECG Belt Analysis of Standard Deviation of Activation Times (SDAT) of LBBP Compared to Native Conduction — 38.6; 20.5 ms

Primary: Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12 — 0.8218; 0.9828 Ratio — p=<0.0001

Primary: Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) — 0.83; 1.08 ratio: endpoint/baseline (pg/mL)

Primary: Percentage of Subjects Classified as "Not Worsened" for Changes in the Minnesota Living With Heart Failure Questionnaire and Six-minute Walk Distance Between Periods of…

Primary: All-cause Death, Heart Failure-related Re-hospitalizations, and a Composite Outcome of Both Death and Heart Failure-related Re-hospitalizations — 36; 15; 41; 18…

Primary: Number of Participants With Left Ventricular (LV)Lead Related Complications — 1 participants

Primary: Difference in Home Systolic Blood Pressure — 130.7; 134.5 mm Hg — p=0.017

Primary: Exercise Tolerance Assessed by 6 Minute Walking Test — 474.8; 435.7; 453.1 meters

Primary: Number of Participants With B-lines ≤ 15 at the Conclusion of ED AHF Management — 7; 10 Participants

Primary: Change in NT-proBNP — 0.14; 0.19 unitless — p=0.45

Primary: Change in Left Ventricular End Systolic Volume (ml) — -4.4; -1.2; -3.8 mL

Primary: Hierarchical Composite Endpoint Composed of Time to Cardiovascular (CV) Death, Time to First Heart Failure (HF) Hospitalization, and Relative Change in NT-proBNP From…

Primary: Change in Aerobic Exercise Capacity — -0.2; 1.0 ml/kg/min

Primary: Composite Value of 3 Variables After 9 Months: Cardiovascular Death (Days Alive), Cardiovascular Hospitalization (Days Out of Hospital), Heart Failure Symptoms (Symptom…

Primary: Acute Haemodynamic Response to Dual Left Ventricular Pacing — 3.7 % difference — p=<0.05

Primary: Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations. — 894; 1009; 690; 797 Events — p=0.0587

Primary: Improvement in Left Ventricular Ejection Fraction (LVEF) at 12 Months — 12; 10; 9 LVEF responders — p=0.685

Primary: Number of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite Endpoints — 30; 28; 0; 0 Participants

Primary: Left Ventricular Diastolic Dysfunction — 2.1; 2; 1.3; 2.2 DD grade

Primary: Resting Systolic BP — 135 mm Hg — p=<0.05